Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology | Genetic Disease
 Disease Category: Hemophilia
Location: United States, CA

Trial Information

Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-Derived von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial

You have been asked to allow your child to participate in this research study because he has severe Hemophilia A. The purpose of this research study is to evaluate whether there is a difference in developing inhibitors between the plasma-derived FVIII concentrates (that also contain the stabilizer of FVIII, von Willebrand Factor (VWF)) and recombinant FVIII concentrates. Your child’s treatment on this study is expected to last about 3 years or 50 days of treatment or until inhibitor development, whichever comes first.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.